Literature DB >> 21455572

Effects of human leukocyte antigen (HLA)-DR engagement on melanoma cells.

Giovanna Barbieri1, Emilio Rimini, Maria Assunta Costa.   

Abstract

Melanoma cells often display constitutive expression of the major histocompatibility complex (MHC) class II molecules which is associated with a higher metastatic dissemination. The MHC class II molecules during T cell/ professional antigen-presenting cell (APC) interactions are localized, as signalling receptors, into membrane lipid rafts which are thought to be sites of signalling complex assembly. Therefore, with the aim of understanding the molecular mechanisms used by melanoma cells to frustrate an effective anti-tumour response we stimulated a MHC class II constitutive expressing melanoma cell line with a specific antibody that mimics the interaction of T-cell receptor (TCR) with class II molecules. In stimulated melanoma cells we showed through Western blotting and immunofluorescence experiments the recruitment of HLA-DR molecules in lipid raft compartments as well as the c-Jun NH2-terminal kinase activations as a consequence of the class II engagement. Furthermore, we showed that SDS-stable HLA-DR-peptide complexes are recruited in lipid rafts of stimulated melanoma cells. Therefore, in light of the results reported, our hypothesis is that the redistribution of class II molecules into lipid raft microdomains of stimulated melanoma cells as well as the associated activation of signalling pathways, could be useful for melanoma cells to frustrate an effective anti-tumour response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455572     DOI: 10.3892/ijo.2011.988

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.

Authors:  Maria I Toki; Christopher R Merritt; Pok Fai Wong; James W Smithy; Harriet M Kluger; Konstantinos N Syrigos; Giang T Ong; Sarah E Warren; Joseph M Beechem; David L Rimm
Journal:  Clin Cancer Res       Date:  2019-06-12       Impact factor: 12.531

2.  Quantitative Analysis of Immune Infiltrates in Primary Melanoma.

Authors:  Robyn D Gartrell; Douglas K Marks; Thomas D Hart; Gen Li; Danielle R Davari; Alan Wu; Zoë Blake; Yan Lu; Kayleigh N Askin; Anthea Monod; Camden L Esancy; Edward C Stack; Dan Tong Jia; Paul M Armenta; Yichun Fu; Daisuke Izaki; Bret Taback; Raul Rabadan; Howard L Kaufman; Charles G Drake; Basil A Horst; Yvonne M Saenger
Journal:  Cancer Immunol Res       Date:  2018-02-21       Impact factor: 11.151

Review 3.  Influence of immune responses in gene/stem cell therapies for muscular dystrophies.

Authors:  Andrea Farini; Clementina Sitzia; Silvia Erratico; Mirella Meregalli; Yvan Torrente
Journal:  Biomed Res Int       Date:  2014-05-19       Impact factor: 3.411

4.  Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, a Candidate Melanoma Suppressor Function.

Authors:  John van Tuyn; Farah Jaber-Hijazi; Douglas MacKenzie; John J Cole; Elizabeth Mann; Jeff S Pawlikowski; Taranjit Singh Rai; David M Nelson; Tony McBryan; Andre Ivanov; Karen Blyth; Hong Wu; Simon Milling; Peter D Adams
Journal:  J Invest Dermatol       Date:  2017-06-22       Impact factor: 8.551

5.  A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas.

Authors:  Laura Gadeyne; Yannick Van Herck; Giorgia Milli; Zeynep Kalender Atak; Maddalena Maria Bolognesi; Jasper Wouters; Lukas Marcelis; Angeliki Minia; Vaia Pliaka; Jan Roznac; Leonidas G Alexopoulos; Giorgio Cattoretti; Oliver Bechter; Joost Van Den Oord; Frederik De Smet; Asier Antoranz; Francesca Maria Bosisio
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

6.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Authors:  Douglas B Johnson; Monica V Estrada; Roberto Salgado; Violeta Sanchez; Deon B Doxie; Susan R Opalenik; Anna E Vilgelm; Emily Feld; Adam S Johnson; Allison R Greenplate; Melinda E Sanders; Christine M Lovly; Dennie T Frederick; Mark C Kelley; Ann Richmond; Jonathan M Irish; Yu Shyr; Ryan J Sullivan; Igor Puzanov; Jeffrey A Sosman; Justin M Balko
Journal:  Nat Commun       Date:  2016-01-29       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.